Our studies can be potentially strengthened by analyzing serial tumor biopsies and plasma obtained during tumor progression or response to therapy, such as CXCR4 inhibition, thus providing more dynamic pictures of B cell response and antibody titer changes. The gene discussed is CXCR4; the disease is neoplasm.